Khojayeva, K.; Zhussipbekkyzy, A.; Balkybayeva, D.; Sabit, K.; Lopes, L.R.; Sagatbekova, K.; Zhakupova, A.; Aljofan, M.
Targeting the Endoplasmic Reticulum Oxidoreductin-1 Alpha–Protein Disulfide Isomerase Redox Interface as a Therapeutic Strategy in Cancer. Biomedicines 2026, 14, 263.
https://doi.org/10.3390/biomedicines14020263
AMA Style
Khojayeva K, Zhussipbekkyzy A, Balkybayeva D, Sabit K, Lopes LR, Sagatbekova K, Zhakupova A, Aljofan M.
Targeting the Endoplasmic Reticulum Oxidoreductin-1 Alpha–Protein Disulfide Isomerase Redox Interface as a Therapeutic Strategy in Cancer. Biomedicines. 2026; 14(2):263.
https://doi.org/10.3390/biomedicines14020263
Chicago/Turabian Style
Khojayeva, Kamilla, Aiym Zhussipbekkyzy, Dilbara Balkybayeva, Karakat Sabit, Lucia Rossetti Lopes, Kamila Sagatbekova, Assem Zhakupova, and Mohamad Aljofan.
2026. "Targeting the Endoplasmic Reticulum Oxidoreductin-1 Alpha–Protein Disulfide Isomerase Redox Interface as a Therapeutic Strategy in Cancer" Biomedicines 14, no. 2: 263.
https://doi.org/10.3390/biomedicines14020263
APA Style
Khojayeva, K., Zhussipbekkyzy, A., Balkybayeva, D., Sabit, K., Lopes, L. R., Sagatbekova, K., Zhakupova, A., & Aljofan, M.
(2026). Targeting the Endoplasmic Reticulum Oxidoreductin-1 Alpha–Protein Disulfide Isomerase Redox Interface as a Therapeutic Strategy in Cancer. Biomedicines, 14(2), 263.
https://doi.org/10.3390/biomedicines14020263
